Faiza Bhatti, MD
Gastroenterology · Saint Louis, MONPI 1144556499
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,733 of the $37,820 with a category attached, or 78.6%. E.r. Squibb & Sons, L.L.C. accounts for 80.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2023 at $13,482 and has fallen 90.8% since, to $1,246 in 2025. Among gastroenterology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 201 payments — averaging $188.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$31K
- Pfizer$4K
- AbbVie$1K
- Bristol Myers Squibb$715
- Takeda Pharmaceuticals U.S.A., Inc.$489
- Johnson & Johnson$273
- plus $1K from 14 others
Across 4 payments — averaging $2355.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$9K
What the payments were for
- Consulting fees$1,2003%
- Speaking & faculty fees$29,73379%
- Travel & lodging$2,7787%
- Food & beverage$4,06911%
- Education$400%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 22 | $30,500 |
| Pfizer | 28 | $3,767 |
| AbbVie | 75 | $1,052 |
| Bristol Myers Squibb | 7 | $715 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $489 |
| Johnson & Johnson | 7 | $273 |
| Sanofi | 9 | $248 |
| Lilly USA, LLC | 9 | $209 |
| Regeneron Healthcare Solutions, Inc. | 6 | $171 |
| Madrigal Pharmaceuticals | 4 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $66 |
| Aimmune Therapeutics, Inc. | 3 | $57 |
| Olympus America Inc. | 2 | $29 |
| Novo Nordisk | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $21 |
| Organon | 1 | $20 |
| Ambu Inc. | 1 | $20 |
| Capsovision, Inc. | 1 | $17 |
| Amgen | 1 | $16 |
| Sandoz | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,820 in reported general payments places this provider in the 90th percentile of 374 gastroenterology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 30 | $804,142 |
| Humira(Cf) PenAdalimumab | 29 | $318,887 |
| EntyvioVedolizumab | 17 | $144,977 |
| Mesalamine | 28 | $24,523 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 37 | $6,251 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 22 | $3,838 |
| Balsalazide Disodium | 20 | $3,079 |
| Famotidine | 116 | $1,882 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 121 | $1,545 |
| Sucralfate | 43 | $1,320 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 30 | $1,210 |
| Cimetidine | 16 | $1,088 |
| Pantoprazole Sodium | 105 | $911 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 51 | $828 |
| Dicyclomine Hcl | 49 | $577 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $273 | $804,14230 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Entyvio | $489 | $144,97717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 374 gastroenterology providers in Missouri.
Other gastroenterology in Saint Louis
- Gregory SayukSaint Louis$1.1M
- Katie SchroederSaint Louis$730K
- David AlpersSaint Louis$616K
- Parakkal DeepakSaint Louis$205K
- Mauricio Lisker MelmanSaint Louis$179K
- Matthew CiorbaSaint Louis$156K
- Bruce BaconSaint Louis$138K
- Jeffrey CrippinSaint Louis$120K
- Vladimir KushnirSaint Louis$118K
- Kayci Huff-HardySaint Louis$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.